Associated Papers
560G>A (rs4986782) (R187Q) Single Nucleotide Polymorphism in Arylamine N-Acetyltransferase 1 Increases Affinity for the Aromatic Amine Carcinogens 4-Aminobiphenyl and N-Hydroxy-4-Aminobiphenyl: Implications for Cancer Risk Assessment.
Doll MA et al.
Frontiers in Pharmacology, 2022
NAT1 genetic variation increases asthma risk in children with secondhand smoke exposure.
Brooks CC et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: a mini review.
Hein DW et al.
Pharmacogenetics and Genomics, 2018
Whole genome sequencing of one complex pedigree illustrates challenges with genomic medicine.
Fang H et al.
Bmc Medical Genomics, 2017
The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.
Tang X et al.
Nucleic Acids Research, 2014
Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.
Mattie M et al.
Neoplasia (new York, N.y.), 2013
Characterization of genetic variation and natural selection at the arylamine N-acetyltransferase genes in global human populations.
Mortensen HM et al.
Pharmacogenomics, 2011
Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity.
Wang D et al.
Pharmacogenetics and Genomics, 2011
N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population.
Djordjevic N et al.
Journal of Clinical Pharmacology, 2011
Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3' untranslated regions.
Zhu Y et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology, 2011
Well-done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: the multiethnic cohort study.
Sharma S et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2010
Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma.
Kilfoy BA et al.
Cancer Causes & Control : Ccc, 2010
N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.
Hein DW
Expert Opinion on Drug Metabolism & Toxicology, 2009
Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis.
Bull LM et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus, 2009
Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1.
Zhu Y et al.
The Pharmacogenomics Journal, 2008
Genotyping panel for assessing response to cancer chemotherapy.
Dai Z et al.
Bmc Medical Genomics, 2008
A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.
Zienolddiny S et al.
Carcinogenesis, 2008
Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer.
Suzuki H et al.
Carcinogenesis, 2008
Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1.
Walraven JM et al.
Drug Metabolism Reviews, 2008
Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer.
Jiao L et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2007
Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer.
Gresner P et al.
Lung Cancer (amsterdam, Netherlands), 2007
Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes.
Gemignani F et al.
Carcinogenesis, 2007
Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma.
Mahid SS et al.
Bmc Medical Genetics, 2007
Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.
Li D et al.
Carcinogenesis, 2006
The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.
Ferraro TN et al.
Epilepsy & Behavior : E&b, 2005
A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer.
Landi S et al.
Pharmacogenetics and Genomics, 2005
A database of single-nucleotide polymorphisms and a genotyping microarray for genetic epidemiology of lung cancer.
Landi S et al.
Experimental Lung Research, 2005
TaqMan real time-polymerase chain reaction methods for determination of nucleotide polymorphisms in human N-acetyltransferase-1 (NAT1) and -2 (NAT2).
Hein DW et al.
Current Protocols in Toxicology, 2005
Single-track sequencing for genotyping of multiple SNPs in the N-acetyltransferase 1 (NAT1) gene.
Soucek P et al.
Bmc Biotechnology, 2004
GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population.
Hung RJ et al.
International Journal of Cancer, 2004
NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant.
Johnson N et al.
Bmc Medical Genetics, 2004
N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
Ricart E et al.
The American Journal of Gastroenterology, 2002
Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck.
Fronhoffs S et al.
Carcinogenesis, 2001
Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1.
Fretland AJ et al.
Pharmacogenetics, 2001
Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility.
Wikman H et al.
Pharmacogenetics, 2001
A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma.
Boissy RJ et al.
International Journal of Cancer, 2000
Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1.
de León JH et al.
Molecular Pharmacology, 2000
N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk.
Bouchardy C et al.
Pharmacogenetics, 1998
Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas.
Lin HJ et al.
Pharmacogenetics, 1998
Identification of a novel allele at the human NAT1 acetyltransferase locus.
Doll MA et al.
Biochemical and Biophysical Research Communications, 1997
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.
Cascorbi I et al.
American Journal of Human Genetics, 1995
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M et al.
Lancet (london, England), 0